Oncocyte $OCX —   Prospective, blinded clinical validation study didnt achieve pre-defined endpoint of improvement now focus on accelerating DetermaRx and DetermaI being commercialized for the clinical and biopharma mkts  #healthcare #stocks #investment pushpin pushpin trade mark